

## Protective Role of Prx (Peroxiredoxin) I and II against H<sub>2</sub>O<sub>2</sub>-Induced Apoptosis of MCF7 Cell Lines

<sup>1</sup>Department of Surgery, <sup>2</sup>Cancer Research Institute, College of Medicine, Seoul National University, Seoul,

<sup>3</sup>Department of Biology, College of Natural Science, Chonnam University, Gwangju,

<sup>4</sup>Department of Surgery, Ehwa Womans University Mokdong Hospital, Seoul, Korea

Soo-Jung Ahn<sup>2</sup>, Ji-Yeon Bae<sup>2</sup>, Ryung-Ah Lee<sup>4</sup>, Wonshik Han<sup>1</sup>,  
Seok Won Kim<sup>1</sup>, Ho-Zoon Chae<sup>3</sup> and Dong-Young Noh<sup>1,2</sup>

**Purpose:** Apoptosis is known to be induced either by direct oxidative damage from oxygen free radicals or hydrogen peroxide, or from their generation in cells by injurious agents. Peroxiredoxin plays an important role in eliminating peroxides generated during metabolism. The aim of this study is to elucidate the role of Prx (peroxiredoxin) enzymes during the cellular response to oxidative stress.

**Methods:** The presence of Prx isoforms was demonstrated by immunoblot analysis using Prx isoforms-specific antibodies, and RT-PCR using Prx isozyme coding sequences. Annexin V-FITC apoptosis detection method was used to measure the cell death following exposure to H<sub>2</sub>O<sub>2</sub>.

**Results:** Treatment of MCF7 cell lines with H<sub>2</sub>O<sub>2</sub> resulted in the dose-dependent expression of Prx I and II. Observed decreases in the mRNA expressions of Prx I and II, analyzed by RT-PCR, correlated well with the results of immunoblot analysis. The treatment of normal breast cell line, MCF10A, with H<sub>2</sub>O<sub>2</sub> resulted in rapid cell death, while the breast cancer cell line, MCF7, was resistant. In addition, we confirmed that Prx I and II transfected MCF10A cells were more prone to cell death than MCF10A transfected with vector alone, after H<sub>2</sub>O<sub>2</sub> treatment.

**Conclusion:** These findings suggest that Prx I and II have an important function as inhibitors of cell death during the cellular response to oxidative stress. (*Journal of Korean Breast Cancer Society* 2003;6:68-74)

**Key Words:** Prx (peroxiredoxin), H<sub>2</sub>O<sub>2</sub>, Breast cancer, Apoptosis, Oxidative stress

### INTRODUCTION

Oxidative stress has been implicated in the normal aging processes and numerous disorders including cancer, muscular atrophy, neurodegenerative diseases and atherosclerosis.(1,2)

Mammalian cells have two metal catalyzed oxidative mechanisms, namely the ascorbate oxidation system and the thiol oxidation system. These can both be inhibited by catalase or glutathione synthetase, which protects them from ROS.(3)

Peroxiredoxin, previously called thioredoxin peroxidase, is a 25 kDa protein that acts in the thiol oxidation system. It was first discovered in yeast in 1994(4) and since more than 100 isoforms, with some sequence homology, have been identified from protozoa(5,6) to mammalian species including the rat, mouse and human. Prx is thought to be of biological importance, because these molecules are highly conserved in eukaryotes and prokaryotes.(7) The gene locus for these proteins is suspected to be in chromosome 13q12.(8) Six Pix isoforms have been reported in humans, namely, NKEF-A, NKEF-B, MER 5, AOE372, TAS and ORF6.(9) These enzymes may have functions other than reductase activity, but their functional roles not yet been established.(10,11) Some investigators have reported that Prx has an anti-apoptotic effect in vitro.(12) A more well-known fact is that catalase and superoxide dismutase can protect cells from different initiators of apoptosis.(13,14) Moreover, H<sub>2</sub>O<sub>2</sub> is thought to be a second messenger in the cell-signaling pathway and therefore, the reductase species may play an important role in cellular phenomena such as cell proliferation, differentiation and immune response. This proliferative action of Prx has only been reported in in vitro studies.(12)

Correspondence: Dong-Young Noh, Department of Surgery, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea. Tel: 02-760-2921, Fax: 02-3673-4250, E-mail: dynoh@plaza.snu.ac.kr.

Received : June 15, 2003 Accepted: June 20, 2003

This study was supported by a grant 04-2000-011-0 from Clinical Research Institute, Seoul National University Hospital

In this study, we used Western immunoblot analysis using Prx isozyme antibodies and RT-PCR using the Prx isozyme coding sequences to determine the expressional pattern of Prx isozymes in the H<sub>2</sub>O<sub>2</sub> treated MCF7 cell line. Also, we measured cell death by flow-cytometry in a H<sub>2</sub>O<sub>2</sub> treated MCF7 cell line.

## METHODS

### 1) Materials

PMSF, leupeptin, aprotinin, Triton X-100, DTT, HEPES and diethylpyrocarbonate (DEPC) were obtained from Sigma, Trizol reagent from Gibco BRL, the First strand cDNA synthesis kit from Boehringer Mannheim, *Taq* DNA polymerase from TaKaRa Shuzo Co, peroxidase conjugated goat anti-rabbit IgG antibody from Jackson ImmunoResearch Laboratories, Inc, and the Enhanced Chemiluminescence Detection (ECL) system from Amersham Corp. Protein concentrations were determined using a protein assay kit from Pierce. The Annexin V-FITC apoptosis detection kit was obtained from BD PharMingen, and rabbit antibodies raised against Prx isozymes were a generous gift from Dr. Ho-Zoon Chae.

### 2) Cell and cell culture

The human mammary carcinoma cell line MCF7 was obtained from the Korean Cell Line Bank and maintained in RPMI1640 with 10 % fetal bovine serum (FBS), containing 100 units of penicillin and 100mg of streptomycin/ml in a 37°C incubator under 5% CO<sub>2</sub>.

### 3) RNA isolation and RT-PCR

Total RNA was isolated from H<sub>2</sub>O<sub>2</sub> treated or control MCF7 cells using Trizol reagent. The RNA pellet obtained was dissolved in diethylpyrocarbonate (DEPC) treated H<sub>2</sub>O. at concentrations of 0.5µg/l to 1.0µg/µl and the stored at -70°C. The quantity and quality of the RNA preparations were determined by measuring absorbance at 260 nm and 280 nm. One microgram of total RNA sample was reverse transcribed using the first strand cDNA synthesis kit with random primer p (dN)<sub>6</sub>, according to the manufacturer's instructions. RT-PCR analysis was performed as previously described. Primers used for amplification were synthesized as follows. The forward primers, which included a Hind III site and the initiation codon, were

5'GGGGCCCAAGCTTATGTCTTCAGGAAATGCTAA3' for PrxI and 5'TTCAAAAAGCTTATGGCCTCCGGTAACG-

CGCG3' for Prx II.

The reverse primers, which included a XbaI site and the stop codon, were

5'CGGGCCTCTAGATCACTTCTGCTTGGAGAAAT3' for Prx I and 5'GGCCCTCTAGACTAATTGTGTTTGGAGAA-3' for Prx II.

The amplification conditions used for Prx I were 35 cycles of 94°C for 30 sec, 65°C for 1 min, and 72°C for 1 min. The amplification conditions used for Prx II were 35 cycles of 94°C for 30 sec, 58°C for 1 min, and 72°C for 1 min. The PCR products were subcloned into pcDNA6B basic vector (Invitrogen) to yield pcDNA6B-prxI, and pcDNA6B-prxII. Clones containing the coding sequences in the correct orientation were selected and used for transfection.

### 4) Transfection of eukaryotic cells

MCF10A cells were plated at a density of 3×10<sup>5</sup> cells/ml/ 60 mm dish and allowed to recover for 24 hr. They were then incubated with 4 µg of appropriate DNA and 20µl of LipofectAMINE<sup>TM</sup> in 3 ml of opti-MEM (Life Technologies, Inc) for 6h, after which 3 ml of Dulbecco's modified Eagle's medium containing 10% fetal bovine serum was added to the transfection mixture and the cells were then incubated for an additional 18 h. The efficacy and reproducibility of transfection were confirmed by immunoblot analysis of the Prx I and Prx II protein in each batch of cells.

### 5) Immunoblot analysis

H<sub>2</sub>O<sub>2</sub> treated or control MCF7 cells were homogenized in 20 mM HEPES (pH 7.2), 150 mM NaCl, 1% Triton X-100, 2% cholic acid, 1 mM EDTA, 1 mM EGTA, 0.1 mM DTT, 10µg/ml leupeptin, 10µg/ml aprotinin, and 10 mM phenylmethylsulfonyl fluoride (PMSF). Protein content was determined by the bicinchoninic acid (BCA) protein assay using bovine serum albumin as a standard. Cell lysates were released by heating samples at 95°C for 10 minutes with Laemmli cooking buffer and then separated by SDS-polyacrylamide gel electrophoresis. Samples were transferred onto nitrocellulose filters and incubated separately with their respective polyclonal antibodies for 2 hours. Immunoreactive bands were visualized using peroxidase conjugated goat anti-rabbit IgG antibody. Detection was performed with the ECL system.

### 6) Annexin V-FITC apoptosis detection

H<sub>2</sub>O<sub>2</sub> treated or control MCF10A and MCF7 cells were washed twice with cold PBS and the cells resuspended in 1x


binding buffer at a concentration of  $1 \times 10^6$  cells/ml. 100  $\mu$ l of this mixture was then transferred to a 5 ml culture tube. 5  $\mu$ l of Annexin V-FITC and 5  $\mu$ l of PI were then added. The cells were gently vortexed and incubated for 15 min at room temperature in the dark, and 400  $\mu$ l of 1x binding buffer was added to each tube. Flow cytometry was then performed within one hour.

### 7) Quantification of autoradiographs

A Biomedlab computing densitometer was used to digitize images. The optical density of bands was analyzed with background subtraction using ImageQuant software

## RESULTS

$H_2O_2$  acts in a concentration-dependent manner to induce cell death in a variety of cell types. To examine the effect of  $H_2O_2$  treatment on Prx expression, MCF7 cells were exposed




**Fig. 1.** Detection of Prx isozymes protein in  $H_2O_2$  treated MCF7 cell by immunoblot analysis and RT-PCR. Expression of Prx by  $H_2O_2$  was found to be concentration dependent. MCF7 were exposed to the indicated concentrations of  $H_2O_2$  for 24 hrs. Western blotting and RT-PCR analysis was performed as described in Materials and Methods. Western blotting was employed to assess the levels of the Prx isozymes (I, II, III, IV, and V) using Prx isozyme-specific antibodies. The same membrane was stripped and re-blotting with Prx isozymes-specific antibodies to demonstrate the equal loading of protein in each lane.

to various doses of the  $H_2O_2$  for 24 hrs. Using five isoform-specific antibodies, we investigated the presence of Prx I, II, III, IV and V by immunoblot analysis and RT-PCR in the  $H_2O_2$ -dose dependent treated MCF7 cell lines. As shown in Fig. 1,  $H_2O_2$  treatment induced Prx expression in a dose-dependent manner. Significant decreases in Prx I and II were detected at  $H_2O_2$  concentrations above 600  $\mu$ M. Western blotting was conducted for Prx III, IV and V, which were not dose-dependently decreased in MCF7 cell lines.

Using designated primers based on the conserved amino acid regions, we determined the presence of Prx I and II mRNAs by RT-PCR versus decreasing  $H_2O_2$ -dose in MCF7 the cell line. For normalization purposes,  $\beta$ -actin was amplified simultaneously. As shown in Fig. 1,  $H_2O_2$  treatment resulted in the expression of Prx in a dose-dependent manner. Significant decreases in Prx I and II were detected at  $H_2O_2$  concentration above 600  $\mu$ M. These results showed that decreases in Prx I and II mRNA expressions were well correlated with the results of immunoblot analysis.

Trypan blue exclusion was employed to assess time-dependent cell viability after the  $H_2O_2$  treatments. As shown in Fig. 2, treatment with  $H_2O_2$  also resulted in a cell death in time-dependent manner.

We also examined expressions of Prx I and II in normal human breast tissues, cancer tissues, and in MCF10A and MCF7, and Prx I and II were detected in normal tissues, cancer tissues, MCF10A and MCF7 by RT-PCR and immunoblot analysis. Fig. 3 shows that Prx I and II were



**Fig. 2.** Cell viability of  $H_2O_2$  time dependent treated MCF7 cells. MCF7 were exposed to 800  $\mu$ M of  $H_2O_2$  for 3, 6 and 24 hrs and surviving cells (those able to exclude trypan blue) were counted. Data are reported as percent survival relative to control (untreated) cells. Data are the means of at least 3 independent experiments and error bars correspond to standard errors of the mean.

overexpressed in human breast cancer tissues and MCF7 versus normal human breast tissues and MCF10A.

H<sub>2</sub>O<sub>2</sub> was found to induce cell death in both MCF10A and MCF7 by annexin V assay. As shown in Fig. 4, we found that H<sub>2</sub>O<sub>2</sub> 800μM treatment in MCF10A cells increased cell death by 39.2%. H<sub>2</sub>O<sub>2</sub> 800μM treatment in MCF7 cells increased cell death by 11.4%.


We also investigated whether Prx I and II are able to protect MCF10A cells from the cell death induced by H<sub>2</sub>O<sub>2</sub> by transiently expressing Prx I and II. The overexpression of

these two proteins in MCF10A transfected cells was confirmed by immunoblot analysis.


As shown in Fig. 5, in response to stimulation by H<sub>2</sub>O<sub>2</sub> 800μM, the survival cells of MCF10A transfected with vector alone increased by 29% and increased by 3.6% in Prx I and II transfected cells.

## DISCUSSION


In mammalian cells, a variety of extracellular stimuli, including tumor necrosis factor-α,<sup>(15)</sup> PDGF,<sup>(16,17)</sup> EGF,<sup>(18-21)</sup> and FGF<sup>(15)</sup> induce a transient increase in the intracellular concentration of H<sub>2</sub>O<sub>2</sub>. The transient nature of receptor-mediated increase in intracellular H<sub>2</sub>O<sub>2</sub> suggests that, in addition to its production, the rapid removal of this molecule is important for receptor signaling. Together with glutathione peroxidase and catalase, peroxiredoxin (which reduces H<sub>2</sub>O<sub>2</sub> to H<sub>2</sub>O) enzymes play an important role in eliminating peroxides generated during metabolism. Oxidative stress may be broadly defined as an imbalance between oxidant production and the antioxidant capacity of the cell to



**Fig. 3.** Expression of Prx I, and II in normal human breast and breast cancer tissues, and in the MCF10A and MCF7 cell lines by immunoblot analysis and RT-PCR.



**Fig. 4.** H<sub>2</sub>O<sub>2</sub> induced cell death in MCF10A and MCF7 cell lines MCF10A and MCF7 cells were left untreated or treated for 6 hr with 800μM H<sub>2</sub>O<sub>2</sub>. Cells were stained with fluorescein isothiocyanate-conjugated annexin V in a buffer containing propidium iodide and analyzed by flow cytometry. For each group of cells, the percentage of early apoptotic cells is shown in the lower right quadrant. Cells in the late stages of apoptosis had compromised membranes and stained for both annexin V and propidium iodide, and are shown in the top left quadrant. Dead cells only incorporate propidium iodide (top right). The lower left quadrant contains the vital population.



**Fig. 5.** H<sub>2</sub>O<sub>2</sub> induced cell death in Prx I transfected MCF10A cells. (A) Expression of Prx I, and II in vector transfected MCF10A and Prx I transfected MCF10A cells by immunoblot analysis and RT-PCR. (B) Vector transfected MCF10A and Prx I transfected MCF10A cells were left untreated or treated for 24 hr with 800 μM H<sub>2</sub>O<sub>2</sub>. The cells were stained with fluorescein isothiocyanate-conjugated annexin V in a buffer containing propidium iodide and analyzed by flow cytometry.

prevent oxidative injury. Thus, Oxidative stress has been implicated in a large number of human diseases including atherosclerosis, pulmonary fibrosis, cancer, neurodegenerative diseases, and aging.(22,23) Yet the relationship between oxidative stress and the pathobiology of these diseases is not clear, largely due to a lack of understanding of the mechanisms by which ROS functions in both normal physiological and disease states. Results from our laboratory demonstrate the overexpression of Prx in human breast cancer tissues.(24) However, we could not find any significant association between Prx overexpression and clinical parameters in these groups.

Apoptosis can be triggered by a variety of signals and pathophysiologic conditions, which include oxidative stress. Moreover, the Inhibition of apoptosis can cause abnormal cellular proliferation and may be connected to cancer development.

Endogenously produced ROI and H<sub>2</sub>O<sub>2</sub> are known to act as

intermediates in apoptotic signaling, based on the finding that ROI generation can be detected in cells undergoing apoptosis. Exposure of cells to low concentrations of exogenous ROI, i.e., H<sub>2</sub>O<sub>2</sub>, also induces apoptotic cell death, whereas higher amounts can cause necrosis.(25)

In the current study H<sub>2</sub>O<sub>2</sub> was added to cells in the presence of serum at concentrations ranging from 200 to 1,000 μM H<sub>2</sub>O<sub>2</sub> in the MCF7 breast cancer cell line. As shown in Figs. 2 and 3, H<sub>2</sub>O<sub>2</sub> treatment resulted in Prx expression in a dose-dependent manner, and significant decreases in Prx I and II were detected at H<sub>2</sub>O<sub>2</sub> concentrations above 600 μM. Moreover, these results, which were obtained by RT-PCR correlated well with those obtained by immunoblot analysis. Furthermore, these results are in accord with a report upon the overexpressions of Prx I, II and III in human breast cancer tissues.(24)

Prx I and II, which are abundant in the cytosol, are likely to play an important role in eliminating H<sub>2</sub>O<sub>2</sub> generated as a

by-product of metabolism in the cytosol.(26) Zhang et al. reported results of a cell transfection study, which linked Prx II and anti-apoptotic activity.(12) Prx was suggested to be an anti-apoptotic factor that inhibits(27) of PARP (poly ADP-ribosyl polymerase) cleavage triggered by diverse stimuli, such as serum deprivation, and etoposide and ceramide treatment, which induce apoptosis.(12,27) Kang et al. reported that Prx I and II might participate in the signaling cascades of growth factors and tumor necrosis factor- $\alpha$  by regulating the intracellular concentration of H<sub>2</sub>O<sub>2</sub>, and found that Prx II is able to inhibit the release of cytochrome C from mitochondria to the cytosol, thus preventing cellular hydrogen peroxide accumulation.(28)

The viabilities of MCF10A and MCF7 were severely compromised over the H<sub>2</sub>O<sub>2</sub> concentration range, which strongly supports the biologic relevance of Prx I and II expressions and the role of Prx in protecting cells against H<sub>2</sub>O<sub>2</sub>-induced cell death (Fig. 4). To more accurately quantitative the fraction of the cells undergoing apoptosis we used the annexin V assay, which provides a way of determining the proportion of cells in the early stages of apoptosis, and the proportion of cells in the later stage of apoptosis, as well as the numbers undergoing necrosis. When MCF10A and MCF7 cells were treated for 6 hr with 800 $\mu$ M H<sub>2</sub>O<sub>2</sub>, cell death was increased about 2.6-fold more in the MCF10A cell-lines as compared to the MCF7 cell line (fig. 4). Furthermore, we investigated whether Prx I and II are able to protect MCF10 cell from cell death in response to H<sub>2</sub>O<sub>2</sub> treatment by transiently expressing Prx I and II in these cells. We found that Prx I and II transfected MCF10A cells resisted H<sub>2</sub>O<sub>2</sub> induced cell death compared with MCF10A cells transfected with vector alone (Fig. 5).

These findings suggest that Prx I and II have important functions as inhibitors of cell death during the cellular response to oxidative stress.

## REFERENCES

- 1) Sarsfian TA, Huang C, Kim A, De Vellis J, Shau H. Expression of the antioxidant gene NKEF in the central nervous system. *Mol Chem Neuropathol* 1998;34(1):39-51.
- 2) Sha H, Huang AC, Farris M, Vazarian M, De Vellis J, Chen W. Thioredoxin peroxidase (natural killer enhancing factor) regulation of activator protein-1 function in endothelial cells. *Biochem Biophys Res Commun* 1988;249(3):683-86.
- 3) Baker A, Payne CM, Briehl MM, Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro, and in vivo. *Cancer Res* 1997;57:5162-67.
- 4) Chae HZ, Chung SJ, Rhee SG. Thioredoxin-dependent peroxide reductase from yeast. *J Biol Chem* 1994;269(44):27670-8.
- 5) Jeong JG, Kang SW, Rhee SG, Kim K. Purification and characterization of second type thioredoxin peroxidase (type II TPx) from *Saccharomyces cerevisiae*. *Biochemistry* 1999;38(2):776-83.
- 6) Salinas G, Fernandez V, Fernandez C, Selkirk ME. *Echinococcus granulosus*: cloning of a thioredoxin peroxidase. *Exp Parasitol* 1998;90(3):298-301.
- 7) Kim HK, Kim SJ, Lee JW, Cha MK, Kim IH. Identification of promoter in the 5'-flanking region of the E. coli thioredoxin-like thiol peroxidase gene: evidence for the existence of oxygen-related transcriptional regulatory protein. *Biochem Biophys Res Commun* 1996;221:641-46.
- 8) Pahl P, Berger R, Hart I, Chae HZ, Rhee SG. Location of TDPX1, a human homologue of the yeast thioredoxin-independent peroxide reductase gene (TPx) to chromosome 13q12. *Genomics* 1995;26:602-46.
- 9) Jin DY, Chae HZ, Rhee SG, Jeang KT. Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. *J Biol Chem* 1997;272(49):30952-61.
- 10) Kowaltowski AJ, Netto LE, Vercesi AE. The thiol-specific antioxidant enzyme prevents mitochondrial permeability transition. Evidence for the participation of reactive oxygen species in the mechanism. *J Biol Chem*. 1998;273(21):12766-9.
- 11) Pedrajas JR, Kosmidou E, Miranda-Vizuete A, Gustagsson J, Wright APH, Spyrou G. Identification and functional characterization of a novel mitochondrial thioredoxin system in *Saccharomyces cerevisiae*. *J Biol Chem* 1999;274(10):6366-73.
- 12) Zhang P, Liu B, Kang SW, Seo MS, Rhee SG, Obeid LM. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. *J Biol Chem* 1997;272(49):30615-18.
- 13) Hampton MB, Orrenius S. Redox regulation of apoptotic cell death in the immune system. *Toxicol Lett* 1998;102-103:355-8.
- 14) Ichimiya S. Murine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of the brain most susceptible to cytotoxic and ischemic injury. *DNA Cell Biol* 1997;16(3):311-21.
- 15) Lo YY, Cruz TF. Involvement of reactive oxygen species in cytokine and growth factor induction of c-fos expression in chondrocytes. *J Biol Chem* 1995;270:11727-30.
- 16) Shibamura M, Kuroki T, Nose K. Release of and phosphorylation of 30 kilodalton proteins as early responses of cell cycle-dependent inhibition of DNA synthesis by transforming growth factor beta 1. *Cell Growth Differ* 1991;2:583-91.
- 17) Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka M, Griending KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. *J Biol Chem* 1998;273:15022-9.
- 18) Barrett EG, Johnston C, Oberdorster G, Finkelstein JN. Silica-

- induced chemokine expression in alveolar type II cells is mediated by TNF- $\alpha$ -induced oxidant stress. *Am J Physiol Lung Cell Mol Physiol* 1999;276:L979-88.
- 19) Factor VM, Kiss A, Weitach JT, Wirth PJ, Thorgeirsson SS. Disruption of redox homeostasis in the transforming growth factor- $\alpha$ /c-myc transgenic mouse model of accelerated hepatocarcinogenesis. *J Biol Chem* 1998;273:15846-53.
  - 20) Nagayasu H, Hamada J, Nakata D, Shibata T, Kobayashi M, Hosokawa M, Takeichi N. Reversible and irreversible tumor progression of a weakly malignant rat mammary carcinoma cell line by in vitro exposure to epidermal growth factor. *Int J Oncol* 1998;12:197-202.
  - 21) Bae YS, Kang SW, Weo MS, Baines IC, Tekle E, Chock PB, Rhee SG. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. *J Biol Chem* 1997;272:217-21.
  - 22) Cross CE, Halliwell B, Borish ET, Pryor WA, Ames BN, Saul RL, McCord JM, Harman D. Oxygen radicals and human disease. *Ann Intern Med* 1987;107:526-45.
  - 23) Halliwell B, Gutteridge JM, Cross CE. Free radicals, antioxidants, and human disease: where are we now? *J Lab Clin Med* 1992;119:598-620.
  - 24) Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ. Overexpression of Peroxiredoxin in human breast cancer. *Anti-cancer Research* 2001;21:2085-90.
  - 25) Dypbukt JM, Ankarcrona M, Burkitt M, Sioholm A, Strom K, Orrenius S, Nicotera P. Different prooxidant levels stimulate growth, trigger apoptosis, or produce necrosis of insulin secretion RINm5F cells. *J Biol Chem* 1994;48:30553-60.
  - 26) Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor- $\alpha$ . *J Biol Chem* 1998;273(11):6297-6302.
  - 27) Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly (ADP-ribose) polymerase by proteinase with properties like ICE. *Nature* 1994;371(22):346-7.
  - 28) Nuriel G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. *Oncogene* 1998;17:3237-45.
-